Regulus Therapeutics (RGLS) Stock Analysis

What Regulus Therapeutics does

Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.

Key metrics

ETFs linked to RGLS

Broad-market and Healthcare sector ETFs an investor holding Regulus Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RGLS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Regulus Therapeutics?

Regulus Therapeutics trades under the ticker RGLS on NASDAQ.

Which exchange is RGLS listed on?

RGLS is listed on NASDAQ.

What sector does Regulus Therapeutics operate in?

Regulus Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RGLS in a portfolio?

PortView shows RGLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.